Home  »  Investing News   »  Quarterly Results Took Shares Of MetLife (MET), Ci...

Quarterly Results Took Shares Of MetLife (MET), Cigna (CI) High, And Merck’s (MRK) Low

MetLife, Inc. (MET) was up +5.12% to $51.9. For the fourth fiscal quarter, the U.S. insurer posted a better-than-expected rise in adjusted earnings, with investment growth and underwriting in some of its U.S. companies. The quarter’s adjusted earnings per share are $2.03, compared to $1.53 and $1.98 a year ago. The income was 20.6 billion dollars, up from 18.2 billion dollars a year ago.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Cigna Corporation (CI) was down -6.4% to $205.38. A lower-than-expected profit for the quarter ended was posted by Connecticut’s U.S. insurer, which also reported better-than-expected sales for the time. Compared to $977 million a year ago, quarterly net income was $4.14 billion, or $11.45 a share. For the year, the company generated $160.4 billion in sales, $8.5 billion in net revenue, and $22.96 per share of earnings. Net income was $6.8 billion in 2020 and $18.45 per share. In 2021, it is projected to be at least $6.95 billion, or $20 per share, with at least $165 billion in sales.

Merck & Co., Inc. (MRK) was down -1.67% to $76.03 for releasing lower-than-expected fourth-quarter results and also confirmed the resignation of Ken Frazier, its chief executive, planned for June. There was $12.5 billion in quarterly revenue, up 5 percent. With acquisition costs and impairments, the GAAP cost per share was 83 cents. Earnings per share adjusted are $1.32. For $12.7 billion in sales, the consensus was $1.38 adjusted EPS. The U.S. biotechnology firm anticipates revenue of between $51.8 billion and $53.8 billion for fiscal 2021, a GAAP EPS of between $5.52 and $5.72, and an adjusted EPS of between $6.48 and $6.68.

Related Posts

VNUE Makes Good Progress

VNUE Inc (VNUE) closed the last session almost stable at $0.0112 after seeing a rise of just 1.82% that brought its market cap to $15.81M.




Download Free eBook For

100% free. stop anytime no spam